Dissolving heart stent trial pulled before it even started

NCT ID NCT05417893

Terminated Disease control Sponsor: Meril Life Sciences Pvt. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to compare a new type of heart stent that slowly dissolves over time (MeRes100) with standard permanent metal stents in people with coronary artery disease. The trial was planned to include about 2,000 participants worldwide, but it was withdrawn before enrolling anyone. Because no patients were treated, we cannot draw any conclusions about the safety or effectiveness of this device.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus-eluting bioresorbable vascular scaffold
What this could lead to: If successful, this could offer a temporary scaffold that dissolves over time, potentially reducing long-term complications compared to permanent metal stents.
What could go wrong: The trial was withdrawn before any patients were enrolled, so no data is available. Earlier studies were small, and bioresorbable scaffolds have had mixed results in the past.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.